Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

Cancer

Volumn 101, Issue 12, 2004, Pages 2760-2770

  Takai, Noriyuki ^a,b   Kawamata, Norihiko ^a   Gui, Dorina ^a   Said, Jonathan W ^a   Miyakawa, Isao ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OITA UNIVERSITY   (Japan)

Author keywords

Acetylation; Apoptosis; Cell cycle; Ovarian carcinoma

Indexed keywords

BUTYRIC ACID; CASPASE 3; CASPASE 9; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NICK END LABELING; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ACETYLATION; ANIMALS; APOPTOSIS; CADHERINS; CASPASE 3; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHROMATIN; FEMALE; HISTONE DEACETYLASES; HISTONES; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 10044225745     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20709     Document Type: Article

References (24)

1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
2. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19:286-293.
3. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 1997;89:349-356.
4. Dhordain P, Lin RJ, Quief S, et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998;26:4645-4651.
5. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185-7191.
6. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174-17179.
7. Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiol (Tokyo). 1990;43:1101-1106.
8. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17:423-430.
9. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.
10. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem. 2000;27:35256-35263.
11. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van KuilenburgAB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737-749.
12. Warrell RP Jr., He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90:1621-1625.
13. Newmark HL, Young CW. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem Suppl. 1995;22:247-253.
14. Kumagai T, O'Kelly J, Said JW, Koeffier HP. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst. 2003;95:896-905.
15. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312.
16. Saelens X, Festjens N, Walle LV, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23:2861-2874.
17. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97:10014-10019.
18. Terao Y, Nishida J, Horiuchi S, et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer. 2001;94:257-267.
19. Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141-1149.
20. Lallemand F, Courilleau D, Sabbah M, Redeuilh G, Mester J. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun. 1996;229:163-169.
21. 1. Mol Cell Biol. 1988;8:1614-1624.
22. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251:1451-1455.
23. Graff JR, Herman JG, Lapidus RL, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55:5195-5199.
24. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol. 1982;19:315-359.